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ontrary to somatic medicine,psychiatric sympto-
matology—with the possible exception of behavioral
symptoms and social consequences—is not readily
described by objective measures. Rather, psychiatric
symptoms are produced by the patient’s perception and
subjective experience.However,this does not preclude
attempts to identify,describe,and correctly quantify this
symptomatology.This can be achieved in a straightfor-
ward manner through psychometric measures,cognitive
and neuropsychological tests,and symptom rating scales.
Associated laboratory findings can also provide data that
correlate with clinical syndromes:in the last few decades,
a range of laboratory measures has become commonly
used in psychiatry,from neuroendocrine assays to brain
imaging,either functional imaging (electroencephalog-
raphy [EEG],quantitative EEG,evoked potentials,sleep
studies,etc) or structural and functional imaging (mag-
netic resonance imaging [MRI],single-photon emission
computed tomography [SPECT], positron emission
tomography [PET],etc).
Psychiatric treatment encompasses a whole array of
approaches,from psychotherapy to psychopharmacology,
electroconvulsive therapy,and clinical hypnosis.It also
includes various types of social intervention.Evaluating
treatment response implies that the patient’s condition,
at baseline and after a fixed duration of treatment,can
be assessed in a scientific manner.Pharmacotherapy and
cognitive-behavioral therapy (CBT) can easily meet this
criterion.Traditionally,psychotherapy,with its emphasis
on the individual case, is considered less amenable to
evaluation of therapeutic response,although there have
been many studies.
1
In many medical situations,treatment aims at reducing
or eliminating symptoms; its efficacy must be assessed
with the same clinical and laboratory criteria that were
used to characterize the disorder. In psychiatry, the
symptoms are often modified or improved,but not sup-
pressed.Another pitfall is that treatment response does
not depend only on the presenting disorder; it is also
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C
Psychiatric symptomatology is often subjective, but it
can be partly made more objective for the purposes of
evaluation. Esquirol was the first modern psychiatrist to
stress the need for a scientific approach to treatment
evaluation. The kinetics of treatment is complex
because different components of the clinical picture
improve at a different pace. Assessment of treatment
requires prior definition of end point, response, and
nonresponse. Response is influenced by several factors,
such as placebo effect, diagnostic category and sub-
types, and patient heterogeneity. Treatment response
may be predicted from clinical and biological parame-
ters. This article lists the main causes of nonresponse,
and suggests how to remedy them. 
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ronment.In Diagnostic and Statistical Manual of Mental
Disorders,Fourth Edition (DSM-IV)
2 parlance,progno-
sis lies as much with Axis II as Axis I. In addition, the
kinetics of treatment response are complex. The
improvement in objective and subjective parameters
may follow different courses. Biological parameters
might improve,whereas the patient’s subjective experi-
ence remains unchanged. As is often the case, the
patient’s subjective experience might improve later than
the apparent remission of the illness,only after the sub-
ject recovers unfettered exercise of his or her mental
life and imagination.The fact that clinical improvement
occurs in consecutive stages should be considered when
choosing parameters for assessment of treatment
response: (i) biological or brain imaging parameters
may be adequate to validate immediate treatment
effect; and (ii) the change in the patient’s subjective
experience may be evidenced later by symptom rating
scales or global functioning scales.As mentioned above,
personality is a key factor for the quality of long-term
treatment response.Additionally, treatment duration
will be influenced by the persistence (or not) of trig-
gering factors, the concomitant presence of a physical
problem, and the patient’s social and emotional envi-
ronment.
Overall,nonresponse to treatment can be considered if
the patient’s objective condition and subjective experi-
ence do not evolve favorably after a therapeutic trial that
was coherent with Axis I and Axis II diagnoses,provided
adequate pharmacological doses were used,initial phys-
ical disorders were controlled,and detrimental extrane-
ous influences were eliminated.
History
Jean Esquirol (1772-1840), a student of Philippe Pinel,
was the first to underline the importance of the statisti-
cal assessment of treatment response.He stated his faith
in evaluation and statistics in his treatise on clinical psy-
chiatry,Des maladies mentales,considérées sous les rap-
ports médical, hygiénique, et médicolégal (1838):“The
physician … must give a sincere report of his cases of
success and failure. … I love statistics in medicine
because I believe that it is useful;therefore,I have been
using statistics to help me in my research into mental ill-
ness for the last 30 years.Statistics is the best instrument
to measure the influence of locality,regimen,and treat-
ment methods.”
3 In his statistics on patients admitted to
the Charenton hospital near Paris over an 8-year
period,he reported that a proportion of 1:3 were cured
and discharged; he added that the rate was as high as
1:2.33 if incurable patients were excluded from the
analysis.
3
In his textbook, Allgemeine Psychopathologie, Karl
Jaspers (1883-1969) had a critical approach to using treat-
ment response as an instrument of knowledge (thera-
peutischer Erfolg als Erkenntnismittel). He warned
against the reticence to report treatment failure,particu-
larly in psychotherapy,and against the physician’s com-
placent belief that the patient’s condition improved
thanks to medical intervention.
4
Therapeutic expectations change with the times.Today,
treatment response is considered mostly in the context
of pharmacotherapy,whose appearance in the 1950s con-
siderably broadened our therapeutic armamentarium.
Expectations were more modest up to the second half of
the 20th century,because therapeutic means were con-
siderably less efficient.The foremost psychotropic agent
was chloral, which was synthesized in 1832 and recog-
nized as a useful hypnotic for anxious or depressed
patients in 1869 by Matthias E.O.Liebreich (1839-1908),
a pharmacologist in Berlin.The less severely ill could be
managed with hypnotism, introduced by Franz Anton
Mesmer (1734-1815) and developed by Jean-Martin
Charcot (1825-1893),or by the “rest cure”introduced in
1875 by the American physician Silas Weir Mitchell
(1829-1914) for the treatment of neurasthenia.Asylum
was the only option for the severely ill.In the 19th cen-
tury,it was accepted that some patients were incurable.
A pessimistic course was part of the theory of degenera-
tion (Bénédict-Augustin Morel [1809-1873]), which
posited that the disease could only worsen from one gen-
eration to the next.
Recently,there has been a tendency to apply more strin-
gent criteria to measure response. For instance, until a
few years ago,regulatory agencies assessed the efficacy
of antipsychotics on the basis of the improvement in psy-
chotic symptoms.Today,cognitive and psychosocial out-
come variables are also required.
The parameters of response
Many parameters may influence response and nonre-
sponse.We will attempt to group them under a few head-
ings.
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84Definition of end point and nonresponse
Treatment response can be evaluated as a continuous
measure, as a score on a rating scale, eg, the Hamilton
Depression Scale (HAM-D), or as a category, such as
improved,in remission,or relapsed.Often,different def-
initions have been used over time to characterize the out-
come of treatments.This inconsistency was a problem in
depression, for instance, and operational criteria have
been proposed to define change points in the course of
the illness.
5 Nierenberg et al proposed that the following
categorical outcomes are more clinically relevant than
the mere improvement in depression rating scale scores:
response (without remission),remission,nonresponse,
partial response,relapse,recurrence,recovery,and,more
recently,depressive breakthrough.
6
Response to treatment supposes that the therapeutic tar-
gets that have been defined a priori—either symptoms
or a syndrome—have been significantly modified by
treatment. If rating scales are used, it is generally
accepted that a change of less than 50% in the initial
score is significant.Changes below that threshold will be
considered as cases of nonresponse or insufficient
response.Insufficient response or nonresponse does not
always reflect the lack of efficacy of the drug treatment
that was chosen;it may be caused by other factors,includ-
ing the patient’s constitution,concomitant somatic illness,
pharmacogenetics (fast or slow drug metabolism), or
environment (food or drug interactions).
Placebo response and other biases
The existence of a placebo response leads to the adop-
tion of strict criteria for genuine response, hence the
requirement of a 50% improvement in rating scale
scores.Placebo response is linked to the patient’s emo-
tional ties with the treatment,the clinician’s charisma,or
the nursing care in hospital.Placebo response wears off
or is less significant when the disorder is protracted,
severe,or chronic.
Independently of drug effect,several factors may influ-
ence response.The natural course of the disease may lead
toward spontaneous cure.For instance,50% of patients
with acute posttraumatic stress disorder (PTSD) will heal
spontaneously within the first year of the traumatic
event.Also,a physician following up a patient in a study
will tend to see him or her as slightly improved with
ongoing treatment, even in the absence of objective
improvement.This “optimistic bias”might arise from the
clinician’s sincere care for the patient,and also from the
fact that success is easier to tolerate than failure.Because
of these biases,it is important to consider double-blind
drug trials as the best source of information on treatment
response rates.
Diagnosis and response
The main purpose of classification is to identify groups of
patients who share similar clinical features,so that suit-
able treatment can be planned and the likely outcome
predicted.
7 As shown in Table I,
8-10 response rates vary
widely in different disorders.In obsessive-compulsive dis-
order (OCD),up to 40% of patients are considered to be
nonresponders to a specific pharmacological treatment.
11
Treatment is notably arduous and protracted for certain
“refractory”disorders.An example is anorexia nervosa,
in which response rates should be evaluated taking into
account the fact that management is long;etiologies are
also heterogeneous,and treatment methods are numer-
ous and varied.Chronic conditions may become notori-
ously intractable,eg,the negative impact of the duration
of untreated psychosis has been proven.Personality dis-
orders may interfere with the treatment of a DSM-IV
Axis I disorder.For instance,depression is much more dif-
ficult to treat in a patient with an obsessive-compulsive
personality than in someone with a phobic personality.
Some diagnostic categories are seldom seen in a pure and
isolated state,but are usually associated with comorbid
conditions,which complicate management and are often
difficult to treat.Comorbidity frequently raises the issue
of a primary or secondary condition.An example is social
phobia,which shows a high lifetime risk of comorbidity
with other psychiatric disorders and conditions,eg,other
anxiety disorders,major depression,and drug or alcohol
abuse.Epidemiological studies have reported comorbid-
ity in 70% to 80% of samples of patients with social pho-
bia.
12Treatment may fail because it is directed at the sec-
ondary problem rather than the underlying social phobia.
In all patients with depression,alcohol or drug problems,
or panic attacks,the alert clinician should routinely ask
about phobic avoidance and fear of scrutiny,in order to
identify a possible underlying social phobia.
10
An important question is whether a specific symptomatic
profile or a specific clinical subtype within a diagnostic
category may better predict treatment response than a
general diagnosis.
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Within a single diagnostic entity,subtypes respond differ-
ently to treatment.For instance,Fava et al
14 proposed the
existence of a subgroup of highly irritable and hostile
depressed patients,who report anger attacks and have a
psychological profile distinct from that of depressed
patients without anger attacks; fluoxetine treatment
appeared to reduce anger and hostility in these patients.
These results suggest that the subgroup of depressed
patients with hostility or anger attacks may have differen-
tial neuroendocrine profiles and a selective antidepressant
response to fluoxetine.However,another study
15 did not
support the hypothesis that angry hostile depressed
patients are more likely to respond to selective serotonin
reuptake inhibitors (SSRIs) than to other classes of med-
ication (desipramine,a primarily noradrenergic reuptake
inhibitor,or venlafaxine,a combined serotonin and nor-
epinephrine reuptake inhibitor).
Heterogeneous patient populations
Patient populations are necessarily heterogeneous in
terms of gender (see article by Rubinow and Moore in
this issue),
16 age,pharmacogenetics,education,motiva-
tion,and insight.Beyond obvious sources of variation,
other characteristics explain why, within a diagnostic
entity,different patients may be respond differently.
17 In
the case of PTSD,American studies have reported that
war trauma victims respond less well than civilian victims.
This was proved in a controlled study by Van der Kolk et
al
18 using fluoxetine or placebo for 5 weeks with 31 vet-
erans and 33 civilians.
Prediction of response
A priori indicators of response to treatment would be
useful because it would decrease the need to wait for
4 weeks of antidepressant therapy to conclude whether
the patient is a responder or not.OCD patients need to
be treated for 6 to 8 weeks before concluding that they
are nonresponders.Predictors may be clinical or biolog-
ical parameters and can be registered at baseline or dur-
ing the course of treatment.
Clinical parameters
The patient’s personal history,such as previous response
to a specific drug,can be most informative,although there
have been few studies on this problem.A few reports have
attempted to evaluate the joint predictive value of a num-
ber of clinical characteristics,usually with the help of mul-
tivariate statistics. For instance, a study by Denys et al
19
aimed to identify clinical predictors of outcome in OCD,
and develop an easily applicable method to predict
response to drug treatment. One hundred and fifty
patients with primary OCD according to DSM-IV criteria
were randomly assigned to an SSRI (paroxetine) or a
serotonin noradrenaline reuptake inhibitor (venlafaxine)
in a 12-week,double-blind,comparison trial.The primary
86
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Table I. Some examples of the proportion of patients responding adequately to treatment. PTSD, posttraumatic stress disorder; NA, not applicable; CGI,
Clinical Global Impression scale; CAPS-2, Clinician-Administered PTSD scale; IES, Impact of Event Scale; CGI-S, Clinical Global Impression—
Severity; CGI-I, Clinical Global Impression—Improvement.
Disorder Drugs No. of patients/ Scales Response rates Reference
controls
Depression Generally antidepressants  NA NA 70%-90% Nierenberg et al,
8 1991
First-episode 
39 patients
patients with Clozapine (open label)
NA
CGI 51.3% Hofer et al,
9 2003
schizophrenia
Multiple-episode  
patients with Clozapine (open label)
56 patients
CGI 46.4% Hofer et al,
9 2003
schizophrenia
NA
12 weeks of double-blind  CAPS-2 total severity score Intent-to-treat 
treatment; sertraline 100 patients IES end-point analysis.
PTSD
(50-200 mg/day)  108 controls CGI-S 60% for sertraline;
Davidson et al,
10 2001
or placebo CGI-I 38% for placeboefficacy parameter was the Yale-Brown obsessive-com-
pulsive scale (Y-BOCS) score,and response to treatment
was prospectively defined as a decrease from baseline
≥35%.A stepwise multivariate analysis was used to iden-
tify predictors.The absence of previous therapy,moderate
baseline obsessive-compulsive symptoms (Y-BOCS score
<23),and low Hamilton Depressive Rating Scale scores
(6-15) were found to be prognostic determinants of good
response to pharmacotherapy.The prognostic ability of the
prediction model to discriminate between responders and
nonresponders was quantified as the area under the
receiver operating characteristic curve (ROC area),which
was 0.71 (95% confidence interval 0.63-0.8),demonstrat-
ing a reasonable discriminatory power.This study is the
first to present a model using prediction to estimate the
probability of treatment response to antidepressants in
OCD patients.Stip et al
20 studied 25 schizophrenic patients
as they switched from a typical to an atypical antipsychotic
(risperidone,clozapine,or quetiapine) with a computer-
ized cognitive assessment at baseline and at end point.The
symptomatic response criterion was a 20% reduction in
Brief Psychiatric Rating Scale (BPRS) or Positive and
Negative Syndrome Scale (PANSS). It was shown that
changes in semantic fluency and orthographic fluency pre-
dicted response.
Biological markers
Measures may be relevant at baseline or during the course
of treatment.Plasma levels are an example of a biological
measure that predicts response.Other biological predic-
tors are obtained from brain imaging techniques. For
instance,Hendler et al found that brain PET measures of
untreated OCD patients during specific symptom provo-
cation could predict response to a 6-month course of treat-
ment by sertraline.
21
The relevance of genetic parameters for pharmacody-
namics,pharmacokinetics,and the genetic prediction of
treatment response are detailed in this volume by
Ackenheil and Weber,
22 Morris-Rosendahl and Fiebich,
23
and Hoehe and Kroslak.
24
Neuroendrocrine parameters might differentiate clinical
subgroups and predict response to treatment.Depressed
patients with anger attacks had blunted prolactin response
to thyrotropin-releasing hormone (TRH) stimulation com-
pared with those without anger attacks.Treatment with flu-
oxetine was followed by an overall increase in prolactin
response to TRH among the depressed patients with anger
attacks.
25 Prolactin response to TRH also tended to predict
the degree of response to treatment.A study by Correa et
al
26 showed that a blunted growth hormone response to
clonidine challenge in depressed patients predicted a bet-
ter antidepressant response to amitryptiline than fluoxetine.
The significance of polysomnographic sleep parameters
in depression—in particular REM sleep latency—has
been extensively studied.
27 P300 event-related potentials
have been shown to be useful for the evaluation of
cholinesterase inhibitor (ChEI) treatment in demented
patients.
20 Centrally acting ChEIs improve cognitive func-
tion in Alzheimer’s disease (AD) and other forms of
dementia.Evaluation of treatment efficacy in dementia is
based mainly on subjective assessment methods such as
standardized neuropsychological tests. An additional
objective tool for the evaluation of drug response would
be most helpful.In a study by Werber et al,
28 32 patients
suffering from dementia of several etiologies were treated
with ChEIs (tacrine in 19 patients,donepezil in 5 patients,
and rivastigmine in 8 patients).Cognitive response was
assessed prior to initiation (baseline) and after 26 weeks,
as optimal tolerated doses were achieved and maintained
(end point).Evaluation included repeated measurements
of Mini-Mental State Examination (MMSE),Alzheimer's
disease assessment scale cognitive part (ADAS-cog),and
P300 event-related potentials. Results demonstrated
improvement of the mean ADAS-cog score by 2.0 points,
while the MMSE score remained almost unchanged.
Mean P300 latency reduced significantly, though mean
amplitudes did not change significantly from baseline to
end point.Significant correlations were found between
mean ADAS-cog and mean P300 latency at baseline and
end point,and between mean MMSE and P300 latency at
baseline and end point.These data suggest that P300 is a
reliable instrument for assessment of cognitive response
to ChEIs in demented patients. Table II shows other
examples of biological measures at baseline that may pre-
dict therapeutic outcome.
21,29-32 However,the proportion of
variance contributed by each biological predictor to the
clinical outcome is not well established.
Management of nonresponse
Causes of nonresponse
Treatment may fail for a wide variety of reasons,which
are more numerous than generally thought. In some
cases,treatment is “doomed from the start,”because the
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tant factors were not properly considered when treat-
ment was initiated. In other cases, problems may arise
from treatment titration or follow-up. Various points
should be considered:
• The patient’s lack of compliance is a frequent cause:
more often than not, the patient does not follow the
physician’s prescription blindly.The individual may be
afraid that a full dose will produce side effects or be
worried about dependence.Sometimes,the patient may
have misunderstood the original instructions.
• The physician may not have considered contraindica-
tions.
• The prescribed dose may be incorrect from the start.If
the dose were titrated,the duration of active treatment
should only be considered from the time the active
dose level was reached. Relapse may have occurred
because treatment was discontinued too soon.
88
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Table II. Examples of baseline predictions of therapeutic outcome. YBOCS, Yale-Brown Obsessive-Compulsive Scale; CGI-I: Clinical Global
Impression–Improvement Score; BPRS, Brief Psychiatric Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale; DSM, Diagnostic
and Statistical Manual of Mental Disorders; OCD, obsessive-compulsive disorder; SPECT, single-photon emission computed tomography; PET,
positron emission tomography; EEG, electroencephalography; MRI, magnetic resonance imaging; NA, not applicable; REM, rapid eye move-
ment; SR, slow release.
Disorder Measure at  Drug No. of  Symptomatic Biological Reference
baseline patients/ response predictor
controls criterion at baseline
OCD (DSM-IV) SPECT  Sertraline, 26 patients YBOCS  Brain perfusion   Hendler et al,
21
at baseline 6 months NA decrease  during symptom  2003
in untreated ≥30% provocation (dorsal- 
patients caudal anterior  
cingulum and 
right caudate)
Treatment- PET Carbamazepine, 32 patients CGI-I much  Baseline (left  Ketter et al,
29
refractory nimodipine 46 controls or very insular and left 1999
DSM-III major much prefrontal)
affective disorder improved metabolism
Schizophrenic  Dopamine Clozapine, 32 patients BPRS Allele Gly-9 Scharfetter et al,
30
patients receptor 6 months NA decrease  and genotype 1999
refractory or D3 genotype ≥50% Gly-9/Gly-9  are
intolerant to associated with
treatment  response
with typical  
antipsychotics 
Unipolar major EEG sleep Open-label 20 patients Depression  Responders showed Ott et al,
30
depressive  responses  treatment  NA ratings an increase in REM  2002
disorder to placebo  with latency following 
(baseline sleep) bupropion SR, bupropion challenge; 
and a single  about  nonresponders
dose of  8 weeks showed a decrease
bupropion SR
(150 mg orally)
Depressed   MRI Various 60 patients MADRS  Patients with small  Hsieh et al,
32
elderly antidepressant NA at 12 weeks right and total  2002
patients medications hippocampal  volumes
were less likely to 
achieve remission• Concomitant drugs (eg, carbamazepine) or dietary
habits may affect the metabolism of the psychotropic
agent. Other metabolic parameters may prevent the
drug from reaching a therapeutic blood level.
• The diagnosis may be incorrect,leading to an inappro-
priate treatment strategy. The diagnosis should be
reviewed and the heterogeneity of the diagnostic cate-
gory considered.For instance,it is well recognized that
anxiety symptoms commonly occur with depressive dis-
orders,and are sometimes the presenting feature.If the
anxiety is treated, there is little response, but if the
depressive disorder is treated,there may be improve-
ment in anxiety as well as in the depressive symptoms.
• A comorbid mental or physical disorder may prevent
symptomatic improvement.Thyroid dysregulation is a
well-known cause of treatment resistance in depression.
The role of an Axis II mental disorder has already been
mentioned.
• The patient may prefer to remain symptomatic because
of psychological benefits of the sick role.
• Lack of response may be due to the severity of the clin-
ical picture or the long duration of untreated psychosis.
• The role of genetic variation in the form of hypome-
tabolism or hypermetabolism of a drug may cause
treatment failure.
22-24,33
Action in cases of nonresponse
The action in cases of nonresponse to treatment can be
deduced from the causes listed above.Possible solutions
include:
• Assessing whether the diagnosis is correct,and particu-
larly whether personality factors interfere.
• Maximizing the response to the same drug (increasing
dose or duration of treatment).Measuring plasma lev-
els (in the case of some antidepressants and antipsy-
chotics, such as haloperidol or clozapine) may help
determine if the dosage should be adjusted.Therapeutic
drug monitoring for some tricyclic antidepressants and
lithium is supported on the basis of clearly defined ther-
apeutic ranges.This is particularly important in individ-
uals whose pharmacokinetic characteristics differ from
that of the general population or are changing as the
result of aging.Serum or plasma samples should be col-
lected once steady-state drug concentrations are
achieved.
• Checking the patient’s metabolic status (normal metab-
olizer or hypermetabolizer). Checking for the con-
comitant administration of other drugs that induce
hepatic enzymes is also useful.
• Changing the drug.The choice of the new drug should
be based on considerations such as side-effect profile
and personal and family history of response to previ-
ous drug treatment.A common practice is to switch to
a drug with different neuropharmacological properties,
eg,choosing an inhibitor of serotonin and norepineph-
rine reuptake,in cases in which treatment with an SSRI
failed.
• Combining drugs within the same class.This is common
in daily clinical practice,even though clinical pharma-
cologists advocate “clean” treatment strategies, with
one drug only.Naturalistic surveys and review of pre-
scription patterns show that most patients with schizo-
phrenia receive more than one antipsychotic.This is
inadequate when two molecules have the same profile
of pharmacological action.
• Treatment augmentation.This strategy involves com-
bining drugs from different classes,eg,the augmenta-
tion of antidepressant treatment with lithium or thyroid
(T3) hormones.
The strategies outlined above represent usual choices
made by psychiatrists.This was demonstrated by Byrne et
al
34 in patients being treated for recurrent major depres-
sion who experienced a return of depressive symptoms
despite a constant maintenance dose of an antidepressant,
a phenomenon known as breakthrough depression. A
total of 145 psychiatrists responded to a survey about
intervention in hypothetical cases of breakthrough depres-
sion in patients taking fluoxetine (20 or 40 mg/day),ser-
traline (100 mg/day),or nortriptyline (100 mg/day).For all
drugs and dosages,the most popular choice was increas-
ing the dosage, followed by augmenting with lithium or
another antidepressant,or changing to a different drug.
Conclusion
The question of nonresponse is clearly important and has
to be considered within the recent evolution of psychi-
atric classification and treatment.
First,traditional classifications are being increasingly crit-
icized for failing to define homogeneous patient groups,
who might respond in a predictable way to a specific
treatment.The fact that psychiatric classification is in a
state of flux is exemplified by the ongoing revision
process of DSM.Research in neuroscience is expected to
play a major part in the preparation of DSM-V.
35 The
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89necessity for a classification that could better guide treat-
ment choice is manifest.
Second, psychopharmacology is changing. There is an
evolution from drugs directed at symptoms toward drugs
directed at syndromes and the pathophysiology of psy-
chiatric disorders. New drugs are being evaluated for
their overall efficacy,eg,for their efficacy on syndromes
and cognition,rather than on a single symptom.More is
required today from treatment methods. Patients and
clinicians are no longer satisfied with a mere reduction
in symptoms.Etiological treatment is an ideal;in some
cases,this ideal might become reality.
The notion of nonresponse is best understood in its his-
torical dimension.Our opinion is still influenced by tra-
ditional thought patterns.However,nonresponse is likely
to be envisaged quite differently in the near future.A few
tasks will remain crucial,such as the definition of criteria
for treatment response, and the delineation of factors
that exert a negative influence on drug efficacy.The prob-
lem of nonresponse exists in all domains of medicine.It
is crucial for patients and their families to understand
that the physicians did all they could and offered the best
available treatments to patients who remained nonre-
sponders. ❑
90
Clinical research
REFERENCES
1. Smith ML, Glass GV, Miller TI. The Benefits of Psychotherapy. Baltimore, Md:
Johns Hopkins University Press; 1980.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental
Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. Esquirol E. Des maladies mentales considérées sous les rapports médical,
hygiénique et médico-légal. Volume 2. Paris, France: Baillière; 1838.
4. Jaspers K. Allgemeine Psychopathologie. 9th ed. Berlin, France: Springer;
1973:692-693.
5. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for
consensus definitions of terms in major depressive disorder. Remission,
recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851-855.
6. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment
response, remission, nonresponse, partial response, and other relevant out-
comes: a focus on treatment-resistant depression. J Clin Psychiatry.
2001;62(suppl 16):5-9.
7. Gelder M, Mayou R, Cowen P. Shorter Oxford Textbook of Psychiatry. Oxford,
UK: Oxford University Press; 2001:87.
8. Nierenberg AA, Keck PE Jr, Samson J, et al. Methodological considera-
tions for the study of treatment-resistant depression. In: Amsterdam JD, ed.
Advances in Neuropsychiatry and Psychopharmacology. Volume 2. Refractory
Depression. New York, NY: Raven; 1991:1-12.
9. Hofer A, Hummer M, Kemmler G, Kurz M, Kurzthaler I, Fleischhacker
WW. The safety of clozapine in the treatment of first- and multiple-episode
patients with treatment-resistant schizophrenia. Int J Neuropsychopharmacol.
2003;6:201-206.
10. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM.
Multicenter, double-blind comparison of sertraline and placebo in the treat-
ment of posttraumatic stress disorder. Arch Gen Psychiatry. 2001;58:485-492.
11. Sasson Y, Zohar J. New developments in obsessive-compulsive disorder
research: implications for clinical management. Int Clin Pharmacol. 1996;11:3-12
12. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social
phobia: comorbidity and morbidity in an epidemiological sample. Arch Gen
Psychiatry. 1992;49:282-288.
13. Montgomery SA. Social phobia: diagnosis, severity and implications for
treatment. Eur Arch Psychiatry Clin Neurosci. 1999;249(suppl 1):S1-S6.
14. Fava M, Rosenbaum JF, Pava JA, McCarthy MK, Steingard RJ, Bouffides
E. Anger attacks in unipolar depression. Part 1. Clinical correlates and
response to fluoxetine treatment. Am J Psychiatry. 1993;150:1158-1163.
15. Bagby RM, Kennedy SH, Schuller DR, et al. Differential pharmacological
treatment response in high angry hostile and low angry hostile depressed
patients: a retrospective analysis. J Affect Disord. 1997;45:161-166.
16. Rubinow, DR, Moore M. Sex-dependent modulation of treatment
response. Dialogues Clin Neurosci. 2004;6:39-51.
17. Foa E, Davidson JRT, Frances A. The Expert Consensus Guideline Series.
Treatment of posttraumatic stress disorder. J Clin Psychiatry. 1999;60(suppl):16.
18. Van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttrau-
matic stress disorder. J Clin Psychiatry. 1994;55:517-522.
19. Denys D, Burger H, Van Megen H, De Geus F, Westenberg H. A score for
predicting response to pharmacotherapy in obsessive-compulsive disorder.
Int Clin Psychopharmacol. 2003;18:315-322.
20. Stip E, Lussier I, Ngan E, Mendrek A, Liddle P. Discriminant cognitive fac-
tors in responder and non-responder patients with schizophrenia. Eur
Psychiatry. 1999;14:442-450.
21. Hendler T, Goshen E, Zwas ST, Sasson Y, Gal G, Zohar J. Brain reactivity
to specific symptom provocation indicates prospective therapeutic outcome
in OCD. Psychiatry Res Neuroimag. 2003;124:87-103.
22. Ackenheil M, Weber K. Differing response to antipsychotic therapy in
schizophrenia: pharmacogenomic aspects. Dialogues Clin Neurosci. 2004;6:71-
77.
23. Morris-Rosendahl, DJ, Fiebich BL. The future of genetic testing for drug
response. Dialogues Clin Neurosci. 2004;6:27-37.
24. Hoehe MR, Kroslak T. Genetic variation and pharmacogenomics: con-
cepts, facts, and challenges. Dialogues Clin Neurosci. 2004;6:5-25.
25. Rosenbaum JF, Fava M, Pava JA, McCarthy MK, Steingard RJ, Bouffides E.
Anger attacks in unipolar depression. Part 2. Neuroendocrine correlates and
changes following fluoxetine treatment. Am J Psychiatry. 1993;150:1164-1168.
26. Correa H, Duval F, Claude MM, et al. Noradrenergic dysfunction and
antidepressant treatment response. Eur Neuropsychopharmacol. 2001;11:163-
168.
27. Riemann D, Berger M, Voderholzer U. Sleep and depression—results
from psychobiological studies: an overview. Biol Psychol. 2001;57:67-103.
28. Werber EA, Gandelman-Marton R, Klein C, Rabey JM. The clinical use of
P300 event-related potentials for the evaluation of cholinesterase inhibitor
treatment in demented patients. J Neural Transm. 2003;110:659-669.
29. Ketter TA, Kimbrell TA, George MS, et al. Baseline cerebral hyperme-
tabolism associated with carbamazepine response, and hypometabolism
with nimodipine response in mood disorders. Biol Psychiatry. 1999;46:1364-
1374.
30. Scharfetter J, Chaudhry HR, Hornik K, et al. Dopamine D3 receptor gene
polymorphism and response to clozapine in schizophrenic Pakistani
patients. Eur Neuropsychopharmacol. 1999;10:17-20.
31. Ott GE, Rao U, Nuccio I, Lin KM, Poland RE. Effect of bupropion SR on
REM sleep: relationship to antidepressant response. Psychopharmacology.
2002;165:29-36.
32. Hsieh MH, McQuoid DR, Levy RM, Payne ME, MacFall JR, Steffens DC.
Hippocampal volume and antidepressant response in geriatric depression.
Int J Geriatr Psychiatry. 2002;17:519-525.
33. Lebrun LH, Villeneuve JP. Hypermetabolism of phenytoin as a cause of
treatment failure. Clin Neuropharmacol. 1983;6:67-70.
34. Byrne S, Rothschild AJ. Psychiatrists’ responses to failure of maintenance
therapy with antidepressants. Psychiatr Serv. 1997;48:835-837.
35. Kupfer DJ, First MB, Regier DA, eds. A Research Agenda for DSM-V.
Washington, DC: American Psychiatric Association; 2002.Treatment goals:response and nonresponse - Macher and Crocq Dialogues in Clinical Neuroscience - Vol 6 . No.1 . 2004
91
Objetivos del tratamiento: respuesta y falta
de respuesta
La sintomatología psiquiátrica a menudo es subje-
tiva, pero para los propósitos de una evaluación
puede ser, en parte, objetivada. Esquirol fue el pri-
mer psiquiatra moderno en dar énfasis a la necesi-
dad de una aproximación científica para la evalua-
ción de un tratamiento. La dinámica del tratamiento
es compleja ya que los diferentes componentes del
cuadro clínico mejoran a un ritmo diferente. La eva-
luación de un tratamiento requiere de la definición
previa del objetivo final, de la respuesta y de la falta
de respuesta. La respuesta está influenciada por
diversos factores como el efecto placebo, las cate-
gorías diagnósticas y los subtipos, y la heterogenei-
dad de los pacientes. La respuesta terapéutica se
puede predecir mediante parámetros clínicos y bio-
lógicos. Este artículo revisa las principales causas de
falta de respuesta terapéutica y sugiere cómo reme-
diarlas.
Objectifs du traitement : réponse et 
non-réponse
La symptomatologie psychiatrique est souvent sub-
jective, mais on peut la rendre en partie plus objec-
tive pour les besoins de l’évaluation. Esquirol a été
le premier psychiatre moderne à souligner la néces-
sité d’une approche scientifique pour l’évaluation
du traitement. La cinétique du traitement est com-
plexe parce que les différentes composantes du
tableau clinique s’améliorent à un rythme différent.
L’évaluation du traitement nécessite une définition
préalable des critères d’évaluation, de la réponse et
de la non-réponse. Plusieurs facteurs influent sur la
réponse, tels les effets du placebo, les catégories et
sous-types de diagnostics et l’hétérogénéité des
patients. La réponse au traitement peut être pré-
vue à partir des paramètres cliniques et biolo-
giques. Cet article passe en revue les principales
causes de non-réponse et propose d’y remédier.